Cumberland Pharmaceuticals Inc (Cumberland Pharma) acquires, develops, and commercializes branded prescription products in the areas of hospital acute care, gastroenterology, and oncology supportive care. The company operates through one reportable segment, specialty pharmaceutical products. The company's marketed products include Acetadote, Omeclamox-Pak, Kristalose, Vaprisol, Caldolor, RediTrex, Sancuso and Vibativ.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

The company's R&D efforts focus on the treatment of hepatorenal syndrome, aspirin exacerbated respiratory disease, systemic sclerosis, portal hypertension, duchenne muscular dystrophy and arthritis and psoriasis. The company is investigating Hepatoren (ifetroban) injection for the treatment of hepatorenal syndrome, Boxaban (ifetroban) oral capsule for patients suffering from aspirin-exacerbated respiratory disease, Vasculan (ifetroban) oral capsule for the treatment of systemic sclerosis and Dyscorban (ifetroban) oral capsule for the treatment of cardiomyopathy associated with duchenne muscular dystrophy in Phase II trials. In FY2022, the company spent US$6.7 million.